Sanofi to terminate investigational program with iniparib, otamixaban
Under the randomized Phase 3 ECLIPSE trial of iniparib in squamous non-small cell lung cancer (Sq NSCLC), patients treated with combination of iniparib and chemotherapy could not achieve
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.